Skip to main content

Table 1 Patient baseline characteristics at the time of initial diagnosis and treatment types (n = 48)

From: Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer

Characteristics Median (range)/no. of patients (%)
Total Group A Group B
No. of patients 48 36 12
Age (yr), median (range) 53 (36–77) 54 (37–68) 47 (36–77)
ECOG performance status score
 0 33 (68.8) 26 (72.2) 7 (58.3)
 1 11 (22.9) 7 (19.4) 4 (33.3)
 2 4 (8.3) 3 (8.3) 1 (8.3)
Histological subtype
 Squamous cell carcinoma 39 (81.3) 32 (88.9) 7 (58.3)
 Small-cell neuroendocrine carcinoma 4 (8.3) 1 (2.8) 3 (25.0)
 Adenocarcinoma 3 (6.3) 2 (5.6) 1 (8.3)
 Adeno-squamous cell carcinoma 1 (2.1)   1 (8.3)
 Sarcoma 1 (2.1) 1 (2.8)  
Primary tumor size (cm)
  ≥ 4-cm 39 (81.3) 30 (83.3) 9 (75.0)
  < 4-cm 9 (18.8) 6 (16.7) 3 (25.0)
Pre-treatment Hb (g/dL)
  > 10 37 (77.1) 29 (80.6) 8 (66.7)
  ≤ 10 11 (22.9) 7 (19.4) 4 (33.3)
Pre-treatment WBC(10^9 /L)
  > 10 8 (16.7) 6 (16.7) 2 (16.7)
  ≤ 10 40 (83.3) 30 (83.3) 10 (83.3)
Diagnostic methods of metastatic lesions
 CT/MRI/ECT 23 (47.9) 18 (50.0) 5 (41.7)
 PET-CT 19 (39.6) 14 (38.9) 5 (41.7)
 Biopsy 6 (12.5) 4 (11.1) 2 (16.7)
Initial treatment
 Chemotherapy cycle 4 (2–8) 4 (2–7) 4 (3–8)
 Pelvic primary tumor radiotherapy 42 (87.5%) 36 (100%) 5 (41.7%)
 Sites of organ metastasis radiotherapy 19 (39.6%) 17 (47.2%) 2 (16.7%)
Primary tumor radiotherapy dose (Gy)
 External dose   45.9 (45–50.4) 37.8 (10.8–46.8)
 ICBT dose   28 (23–34.5)  
 Point A dose (EQD2)   80.4 (72.3–87)  
  1. ECOG Eastern Cooperative Oncology Group, Hb hemoglobin, WBC white blood cell count, MRI magnetic resonance imaging, CT computed tomography, ECT emission computed tomography, PET-CT positron emission tomography-computer tomography, ICBT intracavitary brachytherapy, EQD2 equivalent dose in 2 Gy fractions